Physician profile
Samuel Choulet
NPI 1083025969
$2,295.09
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $698 · 2021: $604.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $806.70 | 2019-2021 | |
| Vifor Pharma, INC. | $290.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $252.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $235.06 | 2019-2020 | |
| Allergan, INC. | $143.06 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $115.90 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.18 | 2020 | |
| Abbvie INC. | $102.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.91 | 2021 | |
| Covidien LP | $63.50 | 2019 | |
| Sk Life Science, INC. | $49.82 | 2021 | |
| Sunovion Pharmaceuticals INC. | $24.74 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Choulet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.